Researchers have come up with an affordable, quick and accurate way to diagnose brain cancer in a fraction of the time that current technology allows. The early results are promising enough that they've patented their new approach.
A team of researchers from Nottingham University in the U.K. have repurposed a bone-healing polymer to achieve something very different: delivery of cancer drugs to tumors in the brain after surgery.
The outlook for young patients diagnosed with medulloblastoma is grim. The highly malignant brain tumor mostly affects children, and treatments are aggressive, often leaving patients with severe side effects, such as lowered IQ levels and increased susceptibility to other cancers.
Researchers at Penn State University have developed microcapsules to deliver brain cancer drugs in a targeted and controlled way--and the consistently uniform particles would be easy to manufacture, they say.
Using a laser-based technique called SRS microscopy, researchers at the University of Michigan Medical School and Harvard University are developing an approach to brain tumor surgery that could help make the procedure more accurate.
Harvard Medical School and Danish researchers developed a new MRI diagnostic technique that can help determine how well patients with aggressive brain cancer will respond to a particular form of treatment.
Getting drugs into the brain to treat tumors and other ailments has for years proven a difficult hurdle to overcome, but neurosurgeons have begun using an MRI-based technique to guide the delivery of gene therapies to target brain cancers in real time.
Roche nabbed a first-line approval for Avastin in brain cancer. Japanese regulators cleared the drug to treat aggressive brain tumors, including newly diagnosed glioblastoma, as monotherapy and in combination with radiation and chemo.
In what may be the first experiment of its kind, researchers have used microvesicles derived from mesenchymal bone marrow cells to treat brain cancer.
In yet another sign that the R&D side of Merck KGaA has derailed and can't get back on track, the pharma giant today said that a late-stage study of a brain cancer drug hopeful had failed to demonstrate signs of efficacy.